Immunogenicity and safety of a SARS-CoV-2 mRNA vaccine (SYS6006) in healthy Chinese participants: A randomized, observer-blinded, placebo-controlled phase 2 clinical trial-Reference-Cited by-同舟云学术

Immunogenicity and safety of a SARS-CoV-2 mRNA vaccine (SYS6006) in healthy Chinese participants: A randomized, observer-blinded, placebo-controlled phase 2 clinical trial

Published:2024-03 Issue:7 Volume:42 Page:1561-1570
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Jin Fei,Qiu Yuanzheng^ORCID,Wu Zhiwei,Wang Yuan-Hui,Cai Chengye,Fu Liangcai,Jiao Wenbin,Wang Huixian,Gao Ming,Su Chang,Ma Jun-Heng,Xu Yan,Huang Chao-Chao,Zhang Qing,Ni Shaonan,Zhao Maosheng,Guo Lixian,Ji Li,Yang Hanyu,Zhao Yuliang,Li Chunlei,Lu Xiang^ORCID,Su Yu-Wen^ORCID,Li Qi

Publisher

Elsevier BV

Reference19 articles.

1. World Health Organization. Coronavirus Disease (COVID-19) Dashboard. Available at: https://covid19.who.int/. Accessed 9 August 2023.

2. Societal impacts of pandemics: comparing COVID-19 with history to focus our response;Patterson;Front Public Health,2021

3. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study;McMenamin;Lancet Infect Dis,2022

4. BNT162b2 mRNA covid-19 vaccine in a nationwide mass vaccination setting;Dagan;N Engl J Med,2021

5. World Health Organization. WHO Health Emergency Dashboard. Available at: https://covid19.who.int/region/wpro/country/cn. Accessed 9 August 2023.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and immunogenicity of heterologous boosting with a bivalent SARS-CoV-2 mRNA vaccine (XBB.1.5/BQ.1) in Chinese participants aged 18 years or more: A randomised, double-blinded, active-controlled phase 1 trial;Vaccine;2024-04